Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2024 on Wednesday, November 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

Staff

Recent Posts

The Hash Corporation Announces Proposed Name Change

Toronto, Ontario--(Newsfile Corp. - November 6, 2024) - The Hash Corporation (CSE: REZN) ("HashCo" or…

11 hours ago

Ardent Health Reports Third Quarter 2024 Results

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health Partners, Inc. (NYSE: ARDT) (“Ardent Health” or the “Company”), a leading…

11 hours ago

KORU Medical Systems to Participate in Upcoming Investor Conferences

  MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

12 hours ago

Scryb Announces Closing of Offering

Toronto, Ontario--(Newsfile Corp. - November 6, 2024) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF)…

12 hours ago

SpeedySwab™ Major Retailers are Excited Over our New Over The Counter Packaging With 18 Months Shelf Life

Attention: Pharmacies, Distributors and Government Agencies. SAN DIEGO, Nov. 6, 2024 /PRNewswire/ -- Biolabs International…

12 hours ago

CyncHealth Selects Health Catalyst to Elevate Health Data Management

SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT),…

12 hours ago